Efficacy And Safety Of Febuxostat In Peritoneal Dialysis Patients With Hyperuricemia: A Pilot Study With One Year Follow-Up

To investigate the efficacy and safety of febuxostat on lowering serum uric acid (SUA) and slowing decline of residual kidney function in peritoneal dialysis (PD) patients with hyperuricemia (HUA). Eighteen PD patients with HUA were recruited in this study, and received febuxostat treatment from 10 mg/d to 40 mg/d to maintain SUA in the target range: 240-420 mu mol/L (4-7 mg/dL) in men and 210-360 mu mol/L (3.5-6 mg/dL) in women. Clinical and biological data was recorded at month 0 (M0) (baseline), M6 and M12, while data at 6 months before the baseline (M-6) was also collected. Among the 18 enrolled participants, 1 case lost follow-up, and 17 cases were included in the final analysis. After febuxostat initiation, SUA was rapidly reduced at M1 compared to M0 (p<0.001). This declining trend was sustained to the end of the study (M12), and the SUA value was decreased at M12 compared with M0 (P<0.001). Residual renal Kt/V (RKt/V) was reduced at M12 compared to M0 (P=0.001) and residual renal creatinine clearance rate (RCCr) declined along the observational time, which was decreased from M0 to M12 (P=0.017). All doses of febuxostat were well tolerated and no adverse effects were observed during treatment. In addition, we found high RKt/V, RCCr, short duration of PD, and low serum creatinine (SCr) were likely to predict achievement of SUA target by univariate logistic regression analysis, but without significance (all 0.05更多